NASDAQ: CMPS

COMPASS Pathways plc

Healthcare | Medical - Care Facilities

$13.95 as of 2026-09-04 22:50 UTC

Market Cap$1.9B

Volume771.1K

COMPASS Pathways plc (NASDAQ: CMPS) is a $1.9B medical - care facilities company trading at $13.95. Figures from SEC EDGAR and market feeds; updated 2026-09-04 22:50 UTC.

What COMPASS Pathways plc does

Compass Pathways is a biotechnology company developing COMP360, a proprietary psilocybin formulation designed to treat serious mental health conditions. The company's initial focus is treatment-resistant depression, for which COMP360 received Breakthrough Therapy designation from the FDA. The company completed Phase 2b clinical trials showing that COMP360 demonstrated statistically significant reductions in depressive symptoms and has advanced to Phase 3 pivotal trials, with both trials achieving their primary endpoints.

Summarized from COMPASS Pathways plc’s SEC filings · Read the filing ↗

Key facts

Quote	22:50 UTC
Price	$13.95
Market cap	$1.9B
Volume	771.1K shares

Price Chart

Interactive chart available in terminalLive price charts with full OHLCV data, volume overlay, and technical indicators.
Open CMPS in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-08-05

2026-08-05Nath KabirChief Executive OfficerF-5,962$67.1K
2026-05-29SANTINI GINOA30,158—
2026-05-29Karydas DaphneA21,110—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q1

Deep Track Capital, LP12,161,496$67.25M+65.8%
TWO SIGMA INVESTMENTS, LP4,470,485$63.26M+73.0%
MARSHALL WACE, LLP4,328,682$61.25M+7.2%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-04-16AuditorChanges in registrant's certifying accountantPwCEstimatedSEC 8-K →
2023-12-07Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-10-26Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com2026-09-03
Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
Yahoo2026-09-02POS
Compass Pathways: Still A Buy, But The Exit Just Got Complicated
Seeking Alpha Feed2026-08-25
Compass Pathways: There Are Different Scenarios To Be Considered In Clinical, Regulatory, And Commercialization
SeekingAlpha2026-08-25
Compass Pathways: Still A Buy, But The Exit Just Got Complicated
SeekingAlpha2026-08-25

Questions this page answers

What does COMPASS Pathways plc do?

Compass Pathways is a biotechnology company developing COMP360, a proprietary psilocybin formulation designed to treat serious mental health conditions.

What is CMPS's valuation?

CMPS trades at $13.95, as of 2026-09-04.

When did CMPS last file with the SEC?

COMPASS Pathways plc's most recent SEC filing on record is a 8-K filed 2026-08-05. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-09-04 22:50 UTC. This page is also available as JSON at /api/data?ticker=CMPS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CMPS and 5,000+ tickers.

Create a free account — keep CMPS

For your agent

GET /api/data?ticker=CMPS

This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt